外周血中Prestin作为潜在生物标志物：在不同听力损失亚型及急性内耳损伤中的差异表达

文献信息

中文摘要

目的： 本探索性研究调查了不同听力损失亚型患者外周血Prestin水平，以评估其作为内耳损伤生物标志物的潜力。
方法： 采用ELISA法测定100名年龄匹配参与者的血浆Prestin水平，包括健康对照组（HCG，n = 23）、传导性听力损失患者（CHLG，n = 29）和单侧突发性感音神经性听力损失患者（USSNHLG，n = 48）。分析了其与听力损失亚型、初始听力图构型及治疗结局的关联。
结果： 总体而言，三组间Prestin水平差异有统计学意义（P < 0.001）。经Bonferroni校正的Dunn检验后，USSNHLG的Prestin水平显著高于HCG（P = 0.019），而CHLG的水平显著低于HCG（P = 0.014）。在USSNHLG内，不同治疗结局患者的Prestin水平未观察到统计学显著差异（P = 0.102）。
结论： 本研究结果证实，急性内耳损伤（USSNHL）与外周血Prestin水平显著升高相关，而持续性声输入减少（CHL）与水平降低相关。然而，当前数据不支持基线Prestin作为USSNHL的预后指标。未来需要采用严格临床分层的大型多中心研究来充分确立其临床效用。

英文摘要

OBJECTIVE: This exploratory study investigated peripheral blood Prestin levels across different hearing loss subtypes to evaluate its potential as a biomarker for inner ear injury.
METHODS: Plasma Prestin levels were measured via ELISA in 100 age-matched participants, comprising a healthy control group (HCG, n = 23) and patients with conductive (CHLG, n = 29) and unilateral sudden sensorineural hearing loss (USSNHLG, n = 48). Associations with hearing loss subtypes, initial audiogram configurations, and treatment outcomes were analyzed.
RESULTS: Overall, Prestin levels varied significantly across the three groups (P < 0.001). Following Dunn's test with Bonferroni correction, Prestin levels in the USSNHLG were significantly higher than those in the HCG (P = 0.019), whereas levels in the CHLG were significantly lower than those in the HCG (P = 0.014). Within the USSNHLG, no statistically significant differences in Prestin levels were observed among patients with different therapeutic outcomes (P = 0.102).
CONCLUSIONS: The present findings confirm that acute inner ear injury (USSNHL) is associated with significantly elevated peripheral blood Prestin levels, whereas persistently reduced acoustic input (CHL) is associated with decreased levels. However, current data do not support baseline Prestin as a prognostic indicator for USSNHL. Future multicenter studies with strict clinical stratification are required to fully establish its clinical utility.